Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry

Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry

ABSTRACT Background Cutaneous Crohn's disease (CCD) is a granulomatous condition of the skin discontiguous from the gastrointestinal tract. Cutaneous disease rarely correlates with intestinal disease and often requires separate treatment. While the use of interleukin‐12/23 (IL‐12/IL‐23) and int...

Full description

Saved in:
Bibliographic Details
Main Authors: G. E. McKay, A. Coromilas, L. Liu, K. S. Shaw, M. Murphy, N. Punyamurthy, K. M. Santiago Soltero, W. Damsky, K. A. Wanat, A. P. Charrow, M. Rosenbach, A. Caplan, C. E. LaSenna, L. Arkin, B. E. Shields
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:JEADV Clinical Practice
Subjects:
interleukin‐12/23 inhibitors
interleukin‐23 inhibitors
metastatic Crohn's disease
risankizumab
ustekinumab
vedolizumab
Online Access:https://doi.org/10.1002/jvc2.615
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jvc2.615

Similar Items